Greenland Mines Ltd. (NASDAQ: GRML) announced that Innovation, Science and Economic Development Canada has granted a patent covering technology exclusively licensed by the company for Klotho-based gene therapies targeting cognition, memory and neurodegenerative diseases. The patent protects the use of the secreted Klotho (“s-KL”) RNA splice variant in genetic therapies and includes 42 claims covering its synthesis, delivery methods and potential application across multiple neurological disorders, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis.
The company said the Canadian patent expands its intellectual property portfolio for Klotho-based therapeutics and complements previously issued patents in the United States, China and Europe. This development is significant as it strengthens Greenland Mines’ position in the biotech space, particularly for its lead candidates KLTO-101 and KLTO-202. Greenland Mines added that process development and manufacturing for lead candidate KLTO-101 is scheduled to begin in August 2026, while KLTO-202 has advanced to GMP manufacturing as the company prepares for regulatory interactions later this year.
The Canadian patent is a key milestone for Greenland Mines, which operates two divisions: mining and biotech. The mining division focuses on the exploration and development of the Skaergaard Project in southeast Greenland and, subject to closing of the previously announced transaction, the Sarfartoq neodymium-praseodymium (Nd-Pr) rare earths project in southwest Greenland. The biotech division includes Klotho’s KLTO‑202 primary indication for ALS. The company’s strategy is centered on building a multi-asset platform with exposure to rare earth magnet materials, precious metals and selected midstream processing opportunities, while advancing its broader North Atlantic Critical Metals Corridor vision linking Greenland resources with allied downstream jurisdictions and industrial infrastructure.
The announcement underscores the potential of Klotho gene therapy to address unmet medical needs in neurodegenerative diseases. With the addition of the Canadian patent, Greenland Mines now has intellectual property protection in multiple key markets, which may facilitate future partnerships and licensing deals. The advancement of KLTO-202 to GMP manufacturing and the scheduled process development for KLTO-101 indicate progress toward clinical development. For more details, the full press release is available at https://ibn.fm/x2pHA.
